{"id":"NCT03249376","sponsor":"Intra-Cellular Therapies, Inc.","briefTitle":"Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-27","primaryCompletion":"2019-03-01","completion":"2019-03-01","firstPosted":"2017-08-15","resultsPosted":"2022-06-03","lastUpdate":"2022-06-03"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Depression"],"interventions":[{"type":"DRUG","name":"Lumateperone","otherNames":["ITI-007"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lumateperone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Ã…sberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline to Day 43","effectByArm":[{"arm":"Lumateperone","deltaMin":-16.7,"sd":0.693},{"arm":"Placebo","deltaMin":-12.12,"sd":0.677}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":47,"countries":["United States","Bulgaria","Colombia","Russia","Serbia","Ukraine"]},"refs":{"pmids":["37103915","34551584"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":188},"commonTop":["Headache","Dizziness","Somnolence","Nauseau"]}}